Sequelae in adults at 12 months after mild‐to‐moderate coronavirus disease 2019 (COVID‐19)

This article has been Reviewed by the following groups

Read the full article

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2021.04.12.21255343: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.


    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    This study has several limitations. First, the absence of a control group may impact on the interpretation of results. The single-centre study design and the relatively small number of sample size may restrict its generalizability. Hospitalized patients were not included in the study. Although this made our cohort more homogeneous, studies comparing the long-term outcomes in inpatients and outpatients are definitely needed. Symptoms were self-reported and based on telephone interview. Though, we tried to perform a comprehensive symptoms assessment by using ad hoc questions and a structured questionnaire, some symptoms may have been undetected. The QoL and depression assessment was performed only at 12-months follow-up. Thus, we were unable to report a worsenig in the QoL and depression scale scores. In conclusion, our study indicates that persistent symptoms of SARS-CoV-2 infection can be detected beyond 12-months from the onset of the illness in more than half of patients with mild-to-moderate disease. Identifying patients at risk for prevention and treatment will be critical to improving outcomes and reducing health costs. Finally, a structured and validated questionnaire for the assessment of symptoms in COVID-19 patients is highly desirable to characterize the full clinical spectrum of long COVID and improve the reliability and reproducibility of clinical studies.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.